Pomerantz LLP Files Class Action Against Nektar Therapeutics Over Disclosures

The legal landscape for mid-cap biotechnology firms has grown increasingly treacherous, as evidenced by the recent class action filing by Pomerantz LLP against Nektar Therapeutics (NKTR). This litigation follows a period of intense volatility for the San Francisco-based biopharmaceutical company, which has struggled to regain its footing after the high-profile failure of its lead oncology candidate, bempegaldesleukin. The lawsuit typically alleges that the company and certain officers made materially false or misleading statements regarding the efficacy and safety of its clinical pipeline, or failed to disclose adverse facts that would have impacted investor valuation. For Nektar, this legal challenge represents a significant hurdle as it attempts to pivot its focus toward its immunology and inflammation programs, including NKTR-0165 and NKTR-255.

Industry context is critical to understanding the weight of this filing. Nektar was once the darling of the immunotherapy sector, securing a massive $3.6 billion partnership with Bristol Myers Squibb (BMS) in 2018. That deal, which included an unprecedented $1.85 billion upfront payment, was predicated on the potential of 'bempeg' to revolutionize treatment when combined with Opdivo. However, a series of clinical trial failures in 2022 across melanoma, renal cell carcinoma, and bladder cancer led to the termination of the partnership and a collapse in Nektar's market capitalization. Class action firms like Pomerantz often target these 'cliff-edge' events, arguing that internal data may have signaled failure long before it was communicated to the public. This pattern of litigation is common in biotech, where the gap between scientific uncertainty and corporate optimism can lead to significant legal exposure.

“

Nektar was once the darling of the immunotherapy sector, securing a massive $3.6 billion partnership with Bristol Myers Squibb (BMS) in 2018.

The implications for Nektar are both financial and reputational. While many biotech class actions are eventually settled through insurance providers, the discovery process can be grueling and distracting for management. Short-term, the company must manage its cash burn—which it has already moved to reduce through significant workforce reductions and pipeline prioritization—while defending against these claims. Long-term, the litigation may complicate future partnership discussions. Potential collaborators may demand more rigorous due diligence or more conservative disclosure agreements to avoid being pulled into secondary litigation. For the broader biotech market, this serves as a reminder of the 'disclosure trap' where companies must balance the need to promote their science with the legal requirement to provide a balanced view of clinical risks.